Abstract 2298
Background
Glioblastoma multiform (GBM) is the most common primary malignant brain tumors. Standard management is maximal safe resection followed by concurrent chemoradiotherapy then adjuvant chemotherapy with temozolomide TMZ. Management of GBM patients also involves medical treatment containing corticosteroids that might have direct effects on tumor cell proliferation and apoptosis. We aimed at discussing the clinical relation between corticosteroids usage in GBM patients, overall survival OS, and progression free survival PFS, according to the records from Clinical Oncology Department, Ain Shams University, Cairo, Egypt.
Methods
Retrospective analysis was performed on 66 adult patients diagnosed with GBM by surgery or imaging criteria between January 2014 and December 2016. Data analysis was performed on October 2017 to assess the relation between corticosteroid dependence (defined as the failure to withdraw the corticosteroids after their initiation during the treatment with radiotherapy and TMZ) with OS and PFS. Patients were arranged in 2 arms according to steroid dependency. Arm (A) was steroid dependent (34 patients) and arm (B) was steroid non-dependent (32 patients).
Results
The median age of the entire cohort was 52.8 years (Range 25-72) with male predominance (68.1%) and 72.7 % of the patients received radiotherapy as their main treatment. 59.1 % of the whole cohort were treated by standard radiotherapy regimen of 60 Gy, while 13.6 % were treated by hypo-fractionation radiotherapy with total dose of 45 Gy. 62.1 % of the patients received TMZ concurrently with radiotherapy. Corticosteroids dependency was statistically significantly correlated to both OS with a median of 2.5 months in the corticosteroids dependent group vs. 13.1 months in the corticosteroids non-dependent group (p < 0.001), and also to PFS with a median of 2.3 in the corticosteroids dependent group vs. 9.4 months in the corticosteroid non- dependent group (p = 0.035).
Conclusions
This study from an Egyptian center shows that dependence on corticosteroids during the course of treatment of GBM patients may affect survival. Larger multicentric studies are needed to elaborate the influence of corticosteroids on the disease course.
Clinical trial identification
Legal entity responsible for the study
Clinical Oncology Department, Ain Shams University, Cairo, Egypt.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract